In a phase I/II study with 33 NSCLC EGFR-mutant patients who had progressed following erlotinib treatment, vorinostat combined with erlotinib only inhibited growth in 28 percent of the patients at 12 weeks following treatment [82]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.